BioMedNewsBreaks Archive - Page 19 of 233

ThursdayMay 08, 2025 3:37 pm

BioMedNewsBreaks — Adageis’ AI-Powered Platform Empowers Smarter Billing, Better Care

Adageis, a healthcare technology company, is transforming how providers manage insurance payments with its AI-driven software platform, designed to enhance transparency, ensure reimbursement, and support the shift to value-based care. By offering real-time insights into expected payments, identifying reimbursement gaps, and evaluating performance, Adageis empowers clinics—especially smaller or new practices—to optimize revenue, negotiate better insurance contracts, and make informed financial decisions. The platform helps providers navigate complex insurance arrangements while improving profitability, quality, and a focus on patient care. With growing interest in the healthcare technology sector, Adageis stands out as a promising investment opportunity. To view the full article,…

ThursdayMay 08, 2025 11:26 am

BioMedNewsBreaks — Scinai Immunotherapeutics Ltd. (NASDAQ: SCNI) Reports $4.8 Million Net Gain in 2024, Driven by Loan-to-Equity Conversion

Scinai Immunotherapeutics (NASDAQ: SCNI), a biopharma company focused on inflammation and immunology treatments and CDMO services, reported a $4.8 million net gain for 2024, reversing a $6.5 million loss in 2023. The improvement was largely due to $14.8 million in financial income from a loan-to-equity conversion. The company posted $658,000 in revenue—its first ever—from its CDMO unit. R&D expenses remained steady at $5.6 million, while G&A costs dropped to $2.6 million. Cash and equivalents totaled $1.9 million at year-end. To view the full press release, visit https://ibn.fm/zHuHv About Scinai Immunotherapeutics Ltd. Scinai is a biopharmaceutical company with two complementary business units. One…

WednesdayMay 07, 2025 12:28 pm

BioMedNewsBreaks — Soligenix Inc. (SNGX) CEO Highlights Pipeline and Strategy in Latest BioMedWire Podcast Episode

Soligenix (SNGX) Chairman and CEO Dr. Christopher Schaber joined IBN’s BioMedWire Podcast to discuss the company’s two-pronged business model, robust late-stage pipeline, and ongoing clinical trials. Schaber emphasized Soligenix’s focus on rare disease therapeutics and its Public Health Solutions segment, which has received over $60 million in non-dilutive U.S. government funding. He also outlined near-term milestones, including a confirmatory Phase 3 trial, active partnership discussions, and continued pursuit of strategic opportunities. To view the full press release, visit https://ibn.fm/cdTsU About Soligenix, Inc. Soligenix is a late-stage biopharmaceutical company focused on developing and commercializing products to treat rare diseases where there…

TuesdayMay 06, 2025 11:44 am

BioMedNewsBreaks — HeartBeam Inc. (NASDAQ: BEAT) Adds Two U.S. Patents to Bolster Cardiac Monitoring IP Portfolio

HeartBeam (NASDAQ: BEAT), a medical technology company advancing personalized cardiac care, announced the issuance of two new U.S. patents that strengthen its intellectual property position. The first patent covers the company’s credit card-sized, cable-free 3D ECG device, which enables real-time cardiac monitoring and symptom capture. The second patent protects its rhythm analysis algorithm, which identifies arrhythmias using continuous signal input and prompts users to collect 3D ECG data when anomalies are detected. These additions expand HeartBeam’s patent count to 20 issued and 34 others pending or allowed, reinforcing its platform ahead of future product extensions and FDA review of its…

TuesdayMay 06, 2025 10:20 am

BioMedNewsBreaks – NextPlat Corp (NASDAQ: NXPL) to Announce Q1 2025 Results on May 15, Hosts Investor Call at 8:30 a.m.

NextPlat (NASDAQ: NXPL, NXPLW), a global e-commerce provider, will release its financial results for the quarter ended March 31, 2025, before market open on May 15. Management will host a conference call at 8:30 a.m. EDT the same day, led by Executive Chairman and CEO Charles M. Fernandez, CFO Cecile Munnik, and President and CEO of Global Operations David Phipps. To view the full press release, visit: https://ibn.fm/ttpQg About NextPlat Corp NextPlat is a global e-commerce platform company created to capitalize on multiple high-growth sectors and markets including technology and healthcare. Through acquisitions, joint ventures and collaborations, the company intends…

MondayMay 05, 2025 9:30 am

BioMedNewsBreaks — VERAXA Biotech AG Launches Bispecific ADC Discovery Alliance with OmniAb (NASDAQ: OABI)

VERAXA Biotech AG, a cancer therapy innovator, and proposed de-SPAC target of Voyager Acquisition Corp. (NASDAQ: VACH), announced a co-discovery alliance with OmniAb Inc. (NASDAQ: OABI) to jointly develop a novel bispecific antibody drug conjugate (“bsADC”) program targeting solid tumors. The collaboration combines OmniAb’s transgenic antibody discovery platform with VERAXA’s proprietary ADC linker and conjugation technology to create next-generation cancer therapeutics. Under the agreement, VERAXA will lead preclinical development using two selected cancer targets, while both companies will co-own the program and share future revenues from its advancement, licensing and commercialization. This marks VERAXA’s second major strategic initiative in six…

MondayMay 05, 2025 9:24 am

BioMedNewsBreaks — HeartBeam Inc. (NASDAQ: BEAT) Appoints CEO Robert Eno to Board of Directors

HeartBeam (NASDAQ: BEAT) a medical technology company advancing personalized cardiac care, has appointed Chief Executive Officer Robert Eno to its Board of Directors, expanding the board from eight to nine members. Eno, who joined the company as president in January 2023 and became CEO in October 2024, brings over 30 years of medtech leadership experience, including launching disruptive technologies. His appointment comes as the company prepares for the commercial launch of its 3D ECG technology, pending FDA clearance of its 12-lead ECG synthesis software. To view the full press release, visit https://ibn.fm/7SiVW About HeartBeam Inc. HeartBeam is a medical technology…

ThursdayMay 01, 2025 2:07 pm

BioMedNewsBreaks — HealthLynked Corp. (HLYK) Launches Upgrade to Empower Patients, Drive Better Outcomes

HealthLynked (OTCQB: HLYK) today announced a major enhancement to its appointment booking capabilities, further expanding patient access to care across its growing network of healthcare providers. “At HealthLynked, our mission is to connect patients with the best possible healthcare, faster and more efficiently,” said Dr. Michael Dent, CEO of HealthLynked. “These latest enhancements expand access to care — whether through in-network booking, concierge appointment requests, or specialty-based provider matching. Just as importantly, our new provider review system gives patients real feedback from other users, helping them make better, more confident decisions about their healthcare. Together, these improvements strengthen the patient…

ThursdayMay 01, 2025 11:27 am

BioMedNewsBreaks — TransCode Therapeutics, Inc. (NASDAQ: RNAZ) Advances Phase 1a Trial of RNA Cancer Therapy TTX-MC138

TransCode Therapeutics (NASDAQ: RNAZ) reported continued progress in its Phase 1a trial of TTX-MC138, an RNA-based therapeutic targeting microRNA-10b in metastatic cancer. Thirteen patients have received at least one dose across four dosing levels, with no significant toxicities observed. Eight patients remain in the trial, with two showing stable disease after seven months. Early PK/PD data indicate target engagement and a dose-response relationship consistent with preclinical findings. The results support advancing the trial to Phase 1b for expanded safety and anti-tumor activity evaluation. To view the full press release, visit https://ibn.fm/ZYCaL About TransCode Therapeutics TransCode is a clinical-stage oncology company…

ThursdayMay 01, 2025 10:25 am

BioMedNewsBreaks — NRx Pharmaceuticals, Inc. (NASDAQ: NRXP) Granted FDA Waiver for $4.3 Million NDA Filing Fee for NRX-100

NRx Pharmaceuticals (NASDAQ: NRXP) announced it has received a $4.3 million New Drug Application filing fee waiver from the FDA for NRX-100, its preservative-free ketamine therapy for suicidal depression. The waiver, granted to small businesses and drugs deemed essential for public health, enables NRx to complete its NDA by the end of Q2 2025 using existing resources. NRX-100 offers a single-patient ketamine formulation without benzethonium chloride, a preservative associated with neurotoxicity. The company aims to secure FDA approval to provide insurance-covered treatment options beyond current off-label use. To view the full press release, visit https://ibn.fm/C6SGv About NRx Pharmaceuticals, Inc. NRx…

News and publishing service for medical and biotechnology related companies

Contact us: 512.354.7000

BioMedNewsBreaks

BioMedNewsBreaks — Adageis’ AI-Powered Platform Empowers Smarter Billing, Better Care

BioMedNewsBreaks — Scinai Immunotherapeutics Ltd. (NASDAQ: SCNI) Reports $4.8 Million Net Gain in 2024, Driven by Loan-to-Equity Conversion

BioMedNewsBreaks — Soligenix Inc. (SNGX) CEO Highlights Pipeline and Strategy in Latest BioMedWire Podcast Episode

BioMedNewsBreaks — HeartBeam Inc. (NASDAQ: BEAT) Adds Two U.S. Patents to Bolster Cardiac Monitoring IP Portfolio

BioMedNewsBreaks – NextPlat Corp (NASDAQ: NXPL) to Announce Q1 2025 Results on May 15, Hosts Investor Call at 8:30 a.m.

BioMedNewsBreaks — VERAXA Biotech AG Launches Bispecific ADC Discovery Alliance with OmniAb (NASDAQ: OABI)

BioMedNewsBreaks — HeartBeam Inc. (NASDAQ: BEAT) Appoints CEO Robert Eno to Board of Directors

BioMedNewsBreaks — HealthLynked Corp. (HLYK) Launches Upgrade to Empower Patients, Drive Better Outcomes

BioMedNewsBreaks — TransCode Therapeutics, Inc. (NASDAQ: RNAZ) Advances Phase 1a Trial of RNA Cancer Therapy TTX-MC138

BioMedNewsBreaks — NRx Pharmaceuticals, Inc. (NASDAQ: NRXP) Granted FDA Waiver for $4.3 Million NDA Filing Fee for NRX-100

Official NewsWire Relationships

BioMedWire Currently Accepts

BioMedWire

Company Search

Site Search